HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $25 price target.
August 07, 2023 | 5:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Longboard Pharmaceuticals (NASDAQ:LBPH) has had its 'Buy' rating reiterated and $25 price target maintained by HC Wainwright & Co.
The reiteration of the 'Buy' rating and maintenance of the $25 price target by HC Wainwright & Co. indicates a positive outlook for Longboard Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100